FDA has approved Bipolar Disorder Treatment cariprazine (Vraylar) capsules, an atypical antipsychotic, indicated for the treatment of adults with schizophrenia as well as bipolar I disorder, based on controlled trials of more than 2,700 individuals.

New Clozapine REMS program changes monitoring, dispensing requirements: Schizophrenia, a severe and disabling brain disorder, affects about one percent of the U.S. population. Approximately 9 out of 10 men with schizophrenia will manifest the disease by age 30, compared with only 2 out of 10 women.

Bipolar disorder Treatment, also known as manic depressive disorder, affects approximately 4 percent of individuals and typically presents at age 25, with a higher prevalence among women. The costs of treating this debilitating mental health illness costs more than twice that of depression, the CDC noted.

Prev1 of 3
Continue Reading on Next Page

Comments are closed.

error: Content is protected !!